Lipid Nanoparticle Vaccine Formulation for Cold Chain Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines lack effectiveness in providing immunity against coronaviruses, such as SARS-CoV-2, due to instability outside the cold chain and limited immune response elicitation, especially in vulnerable populations like infants and older adults, and do not efficiently target spike proteins responsible for viral entry into host cells.
Innovation Solution
A lipid-based nanoparticle vaccine formulation incorporating nucleic acids encoding spike proteins of coronaviruses, including SARS-CoV-2, is developed, utilizing a liposomal delivery system with a positively charged lipid layer to enhance cell targeting and immune response, allowing for stability outside refrigeration and efficient antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines are used, then vaccination can be administered, but they lack effectiveness due to instability outside the cold chain and limited immune response elicitation
Solution Approach 1:
The patent modifies the physical and chemical parameters of the vaccine formulation by incorporating nucleic acids encoding spike proteins into a lipid-based nanoparticle delivery system. This encapsulation changes the stability parameters of the vaccine, allowing it to maintain structural integrity and functionality outside the cold chain while preserving immunogenicity.
Solution Approach 2:
The invention creates a composite vaccine formulation combining nucleic acids (encoding spike proteins) with lipid-based nanoparticle materials. This composite structure provides both the immunogenic functionality of the nucleic acid and the stability properties of the lipid nanoparticle carrier, resolving the contradiction between effectiveness and stability.
2Reliability
If conventional vaccines are used, then vaccination can be administered, but they do not efficiently target spike proteins responsible for viral entry into host cells
Solution Approach 1:
The lipid-based nanoparticle delivery system acts as an intermediary carrier that efficiently delivers nucleic acids encoding spike proteins to host cells. This intermediary system enhances antigen presentation by facilitating cellular uptake and expression of the spike protein, thereby improving immune response elicitation without complicating the manufacturing process.
3Reliability
If a nanoparticle delivery system with positively charged lipid layer is used, then cell targeting and immune response are enhanced, but formulation complexity increases
Solution Approach 1:
The patent modifies the surface charge parameter of the lipid nanoparticle formulation by incorporating positively charged lipids. This parameter change enhances cell targeting efficiency through electrostatic interactions with negatively charged cell membranes while maintaining a relatively simple overall formulation structure that does not require complex manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine formulation induces a strong immune response, generating coronavirus-neutralizing antibodies and providing significant protection against coronaviral infections, with improved stability and flexibility for scalable production and administration.
Implementation Method 1
a primary alkyl amine including a positively charged amino group head and at least a carbon tail
Data Source
AI summary
An immunogenic composition forming a vaccine includes a nanoparticle delivery system comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a nucleic acid encoding a protein from a coronavirus.